Cargando…
Afamelanotide Is Associated with Dose-Dependent Protective Effect from Liver Damage Related to Erythropoietic Protoporphyria
In animal models, melanocyte-stimulating hormones (MSHs) protect the liver from various injuries. Erythropoietic protoporphyria (EPP), a metabolic disorder, leads to the accumulation of protoporphyrin (PPIX). In addition to the most prominent symptom of incapacitating phototoxic skin reactions, 20%...
Autores principales: | Minder, Anna-Elisabeth, Schneider-Yin, Xiaoye, Zulewski, Henryk, Minder, Christoph E., Minder, Elisabeth I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143433/ https://www.ncbi.nlm.nih.gov/pubmed/37109595 http://dx.doi.org/10.3390/life13041066 |
Ejemplares similares
-
Beyond pigmentation: signs of liver protection during afamelanotide
treatment in Swiss patients with erythropoietic protoporphyria, an observational
study
por: Minder, Anna-Elisabeth, et al.
Publicado: (2021) -
Increased phototoxic burn tolerance time and quality of life in patients with erythropoietic protoporphyria treated with afamelanotide – a three years observational study
por: Barman-Aksözen, Jasmin, et al.
Publicado: (2020) -
Advances in the management of erythropoietic protoporphyria – role of afamelanotide
por: Lane, Ashley M, et al.
Publicado: (2016) -
Patient-recorded outcome to assess therapeutic efficacy in protoporphyria-induced dermal phototoxicity: a proposal
por: Minder, Elisabeth I, et al.
Publicado: (2010) -
Modeling the ferrochelatase c.315-48C modifier mutation for erythropoietic protoporphyria (EPP) in mice
por: Barman-Aksözen, Jasmin, et al.
Publicado: (2017)